Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma
Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma作者机构：Department of Dentistry Cathay General Hospital Division of Hematology/Oncology Loma Linda University Cancer Center School of Pharmacy Loma Linda University Division of Medical Oncology and Hematology Department of Internal Medicine Loma Linda University
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2016年第22卷第31期
页 面：7080-7090页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Pancreatic adenocarcinoma Nanovector Nanoparticle albumin-bound paclitaxel Nanoliposomal irinotecan Biomarker
摘 要：Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovectorbased anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.
维普期刊数据库